MARKET

GERN

GERN

Geron Corp
NASDAQ
4.650
+0.190
+4.26%
After Hours: 4.630 -0.02 -0.43% 19:52 06/21 EDT
OPEN
4.430
PREV CLOSE
4.460
HIGH
4.660
LOW
4.400
VOLUME
24.55M
TURNOVER
0
52 WEEK HIGH
5.34
52 WEEK LOW
1.640
MARKET CAP
2.76B
P/E (TTM)
-13.4277
1D
5D
1M
3M
1Y
5Y
After Hours Most Active for Jun 18, 2024 : AQN, NVDA, SNAP, MO, AMZN, CFG, AAPL, KVUE, BAC, GERN, META, GRAB
NASDAQ · 3d ago
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Quantum Corporation shares dipped 44.5% to $0.43 on Tuesday. The company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Reliance Global Group, Inc. Shares jumped 350% in today's mid-day session. NLS Pharmaceutics AG shares rose 166% on Monday.
Benzinga · 3d ago
Weekly Report: what happened at GERN last week (0610-0614)?
Weekly Report · 5d ago
How to Invest in Penny Stocks in 2024: 3 Best Picks
NASDAQ · 06/13 10:00
Geron Initiated at Overweight by Barclays
Dow Jones · 06/11 13:37
Geron Price Target Announced at $9.00/Share by Barclays
Dow Jones · 06/11 13:37
Barclays Initiates Coverage On Geron with Overweight Rating, Announces Price Target of $9
Benzinga · 06/11 13:28
GERON CORPORATION <GERN.O>:  BARCLAYS INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $9
Reuters · 06/11 09:41
More
About GERN
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

Webull offers Geron Corp stock information, including NASDAQ: GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.